Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Mutant RAS–selective dependence on the GEF SOS2 reveals tumor cell sensitivity to kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804 · cited 1×
“Because primary MEFs require cooperating oncogenes in addition to mutant RAS to promote transformation (19), we first generated immortalized MEFs that can be transformed by mutant RAS alone (20).”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“DISCUSSION Driver mutations in the RAS family of GTPases occur in ~30% of human tumors (38, 39).”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 2×
“With the notable exception of covalent KRASG12C-specific inhibitors (34), single-agent approaches have been broadly unsuccessful in limiting growth of KRAS mutant tumors.”
BackgroundVinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., Lomas, C., Mendiola, M., Hardisson, D., & Eccles, S. A. (2012) · BMC Biology · doi:10.1186/1741-7007-10-29 · Cited by 1,024
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 1×
“3 of 15 SOS2 RASGEF activity is required for KRAS-driven transformation KRAS Q61 mutants have lower amounts of GTPase activity than the already reduced activity in G12 and G13 mutants, potentially making them less dependent on GEF activity to restore GTP binding (25).”
BackgroundFibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene
Newbold, R. F., & Overell, R. W. (1983) · Nature · doi:10.1038/304648a0 · Cited by 436
Digital signaling and hysteresis characterize Ras activation in lymphoid cells.
Das, J., Ho, M., Zikherman, J., Govern, C., Yang, M., Weiss, A., Chakraborty, A. K., & Roose, J. P. (2009) · Cell · doi:10.1016/j.cell.2008.11.051 · Cited by 398
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Cited by
SOS GEFs in health and disease
Baltanás, F. C., Zarich, N., Rojas-Cabañeros, J. M., & Santos, E. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188445 · Cited by 100
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Stalnecker, C. A., & Der, C. J. (2020) · Science Signaling · doi:10.1126/scisignal.aay6013 · Cited by 90
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69
“We and others have shown that SOS1 and SOS2 may be important therapeutic targets in KRAS-mutated cancer cells (Jeng et al., 2012; Sheffels et al., 2018; Sheffels et al., 2019), and a specific SOS1 inhibitor (BAY-293) has recently been identified (Hillig et al., 2019).”
BackgroundMethodSelf-citationThe role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
“Furthermore, we showed that in KRAS-mutated cancer cells, RTK-SOS2-WT RAS signaling was necessary to provide adequate PI3K/AKT signaling for cells to survive in anchorage-independent growth conditions (protection from anoikis) [81], but HRAS- and NRAS-mutated cancer cells could survive in anchorage-independent conditi…”
BackgroundSelf-citationProteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y.-C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adt6552 · Cited by 8
Metadata
- Authors
- Sheffels, E., Sealover, N. E., Wang, C., Kim, D. H., Vazirani, I. A., Lee, E., M. Terrell, E., Morrison, D. K., Luo, J., & Kortum, R. L.
- Venue
- Science Signaling
- Published
- 2018-09-04
- Volume
- 11
- Issue
- 546
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2891277144
- Cited by
- 56
- References
- 16
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. https://app.cochat.ai/papers/10.1126/scisignal.aar8371
- The paper
- Sheffels, E., Sealover, N. E., Wang, C., Kim, D. H., Vazirani, I. A., Lee, E., M. Terrell, E., Morrison, D. K., Luo, J., & Kortum, R. L. (2018). Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Science Signaling. https://doi.org/10.1126/scisignal.aar8371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.